Michael David Garrison sold $334k of BDX
EVP & Pres Med.Essntl&BioPharm at BECTON DICKINSON & CO. 1,610 shares at an average of $207.46, traded Jan 15, 2026, filed Jan 16, 2026.
Score components
- +15RoleOfficer
- +15Trade size$334k at market
- +5Share of holdings soldSold 12% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001944816-26-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | MOption exercise Common Stock10b5-1 | +3,054 | $167.91 | $513k | 16,159 | Jan 16, 2026 |
| Jan 15, 2026 | DDisposition to issuer Common Stock10b5-1 | -2,454 | $209.00 | $513k | 13,705 | Jan 16, 2026 |
| Jan 15, 2026 | SOpen-market sale Common Stock10b5-1 | -600 | $209.00 | $125k | 13,105 | Jan 16, 2026 |
| Jan 15, 2026 | SOpen-market sale Common Stock10b5-1 | -1,010 | $206.54 | $209k | 12,095 | Jan 16, 2026 |
| Jan 15, 2026 | MOption exercise Stock Appreciation Rightsderivative10b5-1 | -3,054 | $0.00 | $0 | 0 | Jan 16, 2026 |
Related signals
Other insiders at BECTON DICKINSON & CO and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP, Chief Revenue Officer | $14k 76 shares | -0% | |
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP, Chief Revenue Officer | $12k 75 shares | -0% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP, Chief Revenue Officer | $14k 75 shares | -0% | |
| 34Weak | BECTON DICKINSON & CO | Bertram L Scott director | $174k 953 shares | -3% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP, CRO & Pres. Life Sciences | $15k 75 shares | -0% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP, CRO & Pres. Life Sciences | $15k 74 shares | -0% | |
| 13Weak | BECTON DICKINSON & CO | Michael David Garrison EVP & Pres Med.Essntl&BioPharm | $123k 629 shares | -5% | |
| 0Weak | BECTON DICKINSON & CO | Michael Feld EVP, CRO & Pres. Life Sciences | $15k 75 shares | -0% | |
| 29Weak | BECTON DICKINSON & CO | Bertram L Scott director | $38k 217 shares | -1% | |
| 3Weak | BECTON DICKINSON & CO | Michael Feld EVP & President, Life Sciences | $11k 57 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.